• Explore /
  • Poster
  • / Updated survival from a randomized phase III trial (MPACT) of <i>nab</i>-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.

Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.

Abstract Poster

Authors

null

David Goldstein

Prince of Wales Hospital, Sydney, Australia

David Goldstein , Robert Hassan El Maraghi , Pascal Hammel , Volker Heinemann , Volker Kunzmann , Javier Sastre , Werner Scheithauer , Salvatore Siena , Josep Tabernero , Luis Teixeira , Giampaolo Tortora , Jean-Luc Van Laethem , Rosemary Young , Xinyu Wei , Brian Lu , Alfredo Romano , Daniel D. Von Hoff

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00844649

Citation

J Clin Oncol 32, 2014 (suppl 3; abstr 178^)

DOI

10.1200/jco.2014.32.3_suppl.178

Abstract #

178^

Poster Bd #

A7

Abstract Disclosures

Similar Posters

First Author: Vincent J. Picozzi

First Author: Vincent J. Picozzi

First Author: Vincent J. Picozzi

First Author: Vincent J. Picozzi